| Object iveResearch puerarin on diabetic retinopathy protective effect of puerarin control the clinical use of DR to provide a scientific basis. And through the relevant animal studies, to explore its possible mechanism for the prevention and treatment of diabetic retinopathy medical basis for the study.MethodsClinical Research1.54 cases (people) in patients with diabetic retinopathy were randomly divided into 2 groups, treatment group (puerarin) and the control group (Xuesaitong), treatment group,53 eyes of 27 patients,27 patients in control group 54 eyes.2. Make 20 days for a course of treatment 2 treatment, respectively, to determine its efficacy.3. Observed before and after treatment in patients with diabetic retinopathy Syndrome, visual acuity, retinal hemorrhage, exudation, such as changes in focus and the hemorheology.Experimental study1. Purchase of 70 rats, selected 10 for the normal group, the remaining rats were injected with streptozotocin (STZ) After the modeling is divided into model group, puerarin group, Xuesaitong group, TMP group 4 n= 10, a total of 5 groups.2. Make 20 days for a course of treatment, rats administered 20 days after the eye retina slices from rat.3. Detected by immunohistochemistry in the rat retina protein kinase C (PKC), ResultsResults of clinical studies1. DR treatment group had better treatment, comprehensive efficacy of 86.8%, the treatment group and the control of fundus changes in the treatment group, after treatment, spotting and bleeding two indicators sheet improvement was especially evident with the control group were significantly different (P <0.01).2. Treatment group and control group before and after treatment visual acuity were sig nificantly different, P<0.05; two drugs have effect. Treatment group than the control group.3. Treatment group and control group before treatment was significantly higher wholeblood viscosity before treatment showed no significant difference in the treatment group, hemor heological parameters were improved (P<0.05), the control group not only reduced triglyceride significantly (P> 0.05).4. Treatment group and control group patients could significantly promote retinal bleeding, leakage of the absorption, reduce the fundus fluorescein leakage, reduced retinal capillary non-perfusion area, in the treatment of a course that is obvious when the effect of the end of treatment and two before treatment were significantly different (P<0.05), but at the end of the two treatment groups were compared, no significant difference in efficacy between the two quite.Experimental results1. Puerarin group, Xuesaitong group, Ligustrazine group inhibit PKC expression, compared with model group differences were statistically significant (P<0.01); puerarin Xuesaitong Ligustrazine each group, There was no significant difference (P> 0.05).2. Model group were positive for VEGF protein expressed mainly in parts of the ganglion cell layer, inner nuclear layer, outer plexiform layer and photoreceptor cell layer. Treatment group and the normal group was weakly positive VEGF protein expressed mainly in parts of the ganglion cell layer and inner nuclear layer. Conclus ions1. Puerarin can improve DR Xuesaitong Syndrome patients, the role of puerarin than Xuesaitong.2. Puerarin can better improve vision, improve abnormal blood rheology.3. Xuesaitong puerarin significantly promote the patient's eyes bleeding, leakage of the absorption, fluorescence fundus to reduce leakage, reduce the area of retinal capillary non-perfusion and the role of the two drugs rather.4. Animal experiments show that, PKC and VEGF in the pathological changes in the DR plays a very important role; PKC and the activation of VEGF associated with the development of DR is always.5. Puerarin may inhibit the activation of PKC in retinal tissue, reduced expression of VEGF activity to protect the sugar Diabetic retinal tissue.
|
PDF Full Text Request